Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (7): 631-636.DOI: 10.3969/j.issn.1673-8640.2026.07.003
Previous Articles Next Articles
YANG Peihong, ZHOU Shan, KANG Beipei, YANG Yuqi, LIU Hao, ZHOU Ke(
)
Received:2025-03-19
Revised:2025-11-05
Online:2026-07-30
Published:2026-07-23
CLC Number:
YANG Peihong, ZHOU Shan, KANG Beipei, YANG Yuqi, LIU Hao, ZHOU Ke. Distribution and in vitro drug susceptibility test of Nocardia in Xi'an[J]. Laboratory Medicine, 2026, 41(7): 631-636.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.07.003
| 菌名 | 痰液/株 | 肺泡灌洗液/株 | 脓液/株 | 抽出物/株 | 分泌物/株 | 合计/[株(%)] |
|---|---|---|---|---|---|---|
| 乔治教堂奴卡菌 | 8 | 1 | 0 | 1 | 0 | 10(27.03) |
| 脓肿奴卡菌 | 0 | 3 | 1 | 0 | 1 | 5(13.51) |
| 皮疽奴卡菌 | 1 | 2 | 1 | 0 | 0 | 4(10.81) |
| 天美奴卡菌 | 2 | 2 | 0 | 0 | 0 | 4(10.81) |
| 巴西奴卡菌 | 0 | 0 | 0 | 1 | 3 | 4(10.81) |
| 北京奴卡菌 | 2 | 1 | 0 | 0 | 0 | 3(8.11) |
| 豚鼠耳炎奴卡菌 | 3 | 0 | 0 | 0 | 0 | 3(8.11) |
| 新奴卡菌 | 1 | 0 | 0 | 1 | 1 | 3(8.11) |
| 亚洲奴卡菌 | 0 | 0 | 0 | 1 | 0 | 1(2.70) |
| 菌名 | 痰液/株 | 肺泡灌洗液/株 | 脓液/株 | 抽出物/株 | 分泌物/株 | 合计/[株(%)] |
|---|---|---|---|---|---|---|
| 乔治教堂奴卡菌 | 8 | 1 | 0 | 1 | 0 | 10(27.03) |
| 脓肿奴卡菌 | 0 | 3 | 1 | 0 | 1 | 5(13.51) |
| 皮疽奴卡菌 | 1 | 2 | 1 | 0 | 0 | 4(10.81) |
| 天美奴卡菌 | 2 | 2 | 0 | 0 | 0 | 4(10.81) |
| 巴西奴卡菌 | 0 | 0 | 0 | 1 | 3 | 4(10.81) |
| 北京奴卡菌 | 2 | 1 | 0 | 0 | 0 | 3(8.11) |
| 豚鼠耳炎奴卡菌 | 3 | 0 | 0 | 0 | 0 | 3(8.11) |
| 新奴卡菌 | 1 | 0 | 0 | 1 | 1 | 3(8.11) |
| 亚洲奴卡菌 | 0 | 0 | 0 | 1 | 0 | 1(2.70) |
| 抗菌药物 | 微量肉汤稀释法/[株(%)] | E试验/[株(%)] |
|---|---|---|
| 阿米卡星 | 0(0.00) | 0(0.00) |
| 利奈唑胺 | 0(0.00) | 0(0.00) |
| 复方磺胺甲噁唑 | 1(2.70) | 0(0.00) |
| 亚胺培南 | 8(21.62) | 6(16.22) |
| 阿莫西林-克拉维酸 | 5(13.51) | 7(18.92) |
| 头孢曲松 | 6(16.22) | 7(18.92) |
| 妥布霉素 | 7(18.92) | 4(10.81) |
| 米诺环素 | 4(10.81) | 0(0.00) |
| 多西环素 | 11(29.73) | 0(0.00) |
| 莫西沙星 | 12(32.43) | 10(27.03) |
| 克拉霉素 | 21(56.76) | 19(51.35) |
| 环丙沙星 | 24(64.86) | 23(62.16) |
| 抗菌药物 | 微量肉汤稀释法/[株(%)] | E试验/[株(%)] |
|---|---|---|
| 阿米卡星 | 0(0.00) | 0(0.00) |
| 利奈唑胺 | 0(0.00) | 0(0.00) |
| 复方磺胺甲噁唑 | 1(2.70) | 0(0.00) |
| 亚胺培南 | 8(21.62) | 6(16.22) |
| 阿莫西林-克拉维酸 | 5(13.51) | 7(18.92) |
| 头孢曲松 | 6(16.22) | 7(18.92) |
| 妥布霉素 | 7(18.92) | 4(10.81) |
| 米诺环素 | 4(10.81) | 0(0.00) |
| 多西环素 | 11(29.73) | 0(0.00) |
| 莫西沙星 | 12(32.43) | 10(27.03) |
| 克拉霉素 | 21(56.76) | 19(51.35) |
| 环丙沙星 | 24(64.86) | 23(62.16) |
| 抗菌药物 | EA | VME | ME | CA |
|---|---|---|---|---|
| 阿米卡星 | 89.19 | 0.00 | 0.00 | 100.00 |
| 利奈唑胺 | 83.78 | 0.00 | 0.00 | 100.00 |
| 复方磺胺甲噁唑 | 86.49 | 0.00 | 2.78 | 97.30 |
| 亚胺培南 | 72.97 | 37.50 | 0.00 | 91.89 |
| 阿莫西林-克拉维酸 | 83.78 | 20.00 | 3.13 | 81.08 |
| 头孢曲松 | 70.27 | 0.00 | 0.00 | 75.68 |
| 妥布霉素 | 78.38 | 28.57 | 0.00 | 86.49 |
| 米诺环素 | 48.65 | 100.00 | 0.00 | 62.16 |
| 多西环素 | 54.05 | 27.27 | 0.00 | 56.76 |
| 莫西沙星 | 72.97 | 9.09 | 0.00 | 67.57 |
| 克拉霉素 | 70.27 | 9.52 | 25.00 | 78.38 |
| 环丙沙星 | 56.76 | 0.00 | 0.00 | 91.89 |
| 抗菌药物 | EA | VME | ME | CA |
|---|---|---|---|---|
| 阿米卡星 | 89.19 | 0.00 | 0.00 | 100.00 |
| 利奈唑胺 | 83.78 | 0.00 | 0.00 | 100.00 |
| 复方磺胺甲噁唑 | 86.49 | 0.00 | 2.78 | 97.30 |
| 亚胺培南 | 72.97 | 37.50 | 0.00 | 91.89 |
| 阿莫西林-克拉维酸 | 83.78 | 20.00 | 3.13 | 81.08 |
| 头孢曲松 | 70.27 | 0.00 | 0.00 | 75.68 |
| 妥布霉素 | 78.38 | 28.57 | 0.00 | 86.49 |
| 米诺环素 | 48.65 | 100.00 | 0.00 | 62.16 |
| 多西环素 | 54.05 | 27.27 | 0.00 | 56.76 |
| 莫西沙星 | 72.97 | 9.09 | 0.00 | 67.57 |
| 克拉霉素 | 70.27 | 9.52 | 25.00 | 78.38 |
| 环丙沙星 | 56.76 | 0.00 | 0.00 | 91.89 |
| [1] |
Shen J, Du B, Liu Z, et al. Multicenter systematic review of clinical characteristics,diagnostic optimization,and personalized treatment for brain Nocardia infections[J]. Microb Pathog, 2025, 198:107147.
DOI URL |
| [2] | Gurnani B, Moshirfar M. Nocardia keratitis[M]. Treasure Island(FL): StatPearls Publishing, 2025. |
| [3] |
Li T, Cui H, Ma W, et al. Nephrotic syndrome complicated with disseminated Nocardia sepsis:a case report and literature review[J]. BMC Infect Dis, 2025, 25(1):608.
DOI |
| [4] |
Lutfor A B, Afroz S, Mahmud A M, et al. Nocardia infection causing non-healing surgical wounds:a case series from Bangladesh[J]. Int J Infect Dis, 2021, 110:272-278.
DOI URL |
| [5] |
Yang J, Ren H T, Wang J, et al. Clinical characteristics,susceptibility profiles,and treatment of nocardiosis:a multicenter retrospective study in 2015-2021[J]. Int J Infect Dis, 2023, 130:136-143.
DOI URL |
| [6] |
Bai Y, Liu K, Chen Y, et al. Disseminated Infection of Nocardia farcinica in an immunocompetent adult:mistaken for tuberculosis bacilli in acid-fast staining of bronchoalveolar lavage fluid[J]. J Cytol, 2021, 38(2):106-108.
DOI URL |
| [7] | Clinical and Laboratory Standards Institute. Susceptibility testing of Mycobacteria,Nocardiae spp,and other aerobic acintomycetes[S]. M24-A2,CLSI, 2011. |
| [8] | Clinical and Laboratory Standards Institute. Performance standards for antimicrbial susceptibility testing[S]. M100-28ed,CLSI, 2018. |
| [9] |
McTaggart L R, Chen Y, Poopalarajah R, et al. Incubation time and culture media impact success of identification of Nocardia spp. by MALDI-ToF mass spectrometry[J]. Diagn Microbiol Infect Dis, 2018, 92(4):270-274.
DOI URL |
| [10] |
Rodríguez-temporal D, Zvezdánova M E, Benedí P, et al. Identification of Nocardia and non-tuberculous Mycobacterium species by MALDI-TOF MS using the VITEK MS coupled to IVD and RUO databases[J]. Microb Biotechnol, 2023, 16(4):778-783.
DOI URL |
| [11] | Conville P S, Brown-elliott B A, Smith T, et al. The complexities of Nocardia taxonomy and identification[J]. J Clin Microbiol, 2017, 56(1):e01419-17. |
| [12] |
Carrasco G, Valdezate S, Garrido N, et al. GyrB analysis as a tool for identifying Nocardia species and exploring their phylogeny[J]. Clin Microbiol, 2015, 53(3):997-1001.
DOI URL |
| [13] |
Gnanam H, Rajapandian S G K, Gunasekaran R, et al. Molecular identification of Nocardia species causing endophthalmitis using multilocus sequence analysis(MLSA):a 10-year perspective[J]. J Med Microbiol, 2020, 69(5):728-738.
DOI URL |
| [14] |
Valdezate S, Garrido N, Carrasco G, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain[J]. J Antimicrob Chemother, 2017, 72(3):754-761.
DOI PMID |
| [15] |
Uner M C, Hasçelik G, Müştak H K. Antimicrobial susceptibilities of clinical Nocardia isolates identified by 16S rRNA gene sequence analysis[J]. Mikrobiyol Bul, 2016, 50(1):11-20.
DOI URL |
| [16] |
Lebeaux D, Bergeron E, Berthet J, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates:a retrospective analysis of data from a French expert laboratory,2010-2015[J]. Clin Microbiol Infect, 2019, 25(4):489-495.
DOI URL |
| [17] |
Lowman W, Aithma N. Antimicrobial susceptibility testing and profiling of Nocardia species and other aerobic actinomycetes from South Africa:comparative evaluation of broth microdilution versus the E test[J]. J Clin Microbiol, 2010, 48(12):4534-4540.
DOI URL |
| [18] |
Takamatsu A, Yaguchi T, Tagashira Y, et al. Nocardiosis in Japan:a multicentric retrospective cohort study[J]. Antimicrob Agents Chemother, 2022, 66(2):e0189021.
DOI URL |
| [19] |
Yassin A F, Rainey F A, Steiner U. Nocardia cyriacigeorgici sp. nov[J]. Int J Syst Evol Microbiol, 2001, 51(Pt 4):1419-1423.
DOI URL |
| [20] |
Root H, Daniels L, Marx A, et al. Sulfonamides without trimethoprim in the treatment of Nocardia infections:a case report and literature review[J]. Transpl Infect Dis, 2021, 23(1):e13452.
DOI URL |
| [21] |
Huang L, Chen X, Xu H, et al. Clinical features,identification,antimicrobial resistance patterns of Nocardia species in China:2009-2017[J]. Diagn Microbiol Infect Dis, 2019, 94(2):165-172.
DOI URL |
| [22] |
Wang H, Zhu Y, Cui Q, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China,2009 to 2021[J]. Microbiol Spectr, 2022, 10(2):e0156021.
DOI URL |
| [1] | WENG Wenhao. Iteration of laboratory diagnostic technologies for colorectal cancer:from early screening optimization to precise monitoring of MRD [J]. Laboratory Medicine, 2026, 41(4): 309-317. |
| [2] | FAN Yongbing, SHI Mengge, QU Linlin. Research progress on the application of MALDI-TOF MS in the diagnosis and monitoring of colorectal cancer [J]. Laboratory Medicine, 2026, 41(4): 318-325. |
| [3] | CHEN Tian, CAI Qinzhen, TAO Yuxuan, WANG Jun, SHANG Yu, WU Mo, TUO Wenbin, YUAN Chunhui, XIANG Yun. Research progress on laboratory diagnostic methods for Mycoplasma pneumonia [J]. Laboratory Medicine, 2026, 41(3): 299-306. |
| [4] | JI Xiongjuan, LIU Xiaoduo, JIANG Haifei, CHEN Juan, YIN Zhaohua, CHEN Yong, SONG Rongrong, LI Qian, MA Xu, SUN Xibin, ZHOU Weiping. Screening of deafness genes in 11 256 newborns in Tongzhou District,Jiangsu Province and its clinical significance [J]. Laboratory Medicine, 2026, 41(2): 144-149. |
| [5] | LÜ Na, LI Fangning, BAI Qi, ZHAO Mingliang, LI Youran, CAO Yan, ZHAI Yanhong, LI Na, CAO Zheng. Correlation between short stature,tic disorders and mineral elements in whole blood [J]. Laboratory Medicine, 2025, 40(8): 742-750. |
| [6] | SUN Xiangyang, DING Hui, CHEN Minghui, YAO Jiameng, SUN Hanxiao, LIN Jinpiao, SHENG Huiming. An improved POCT of urinary albumin/creatinine ratio for CKD screening [J]. Laboratory Medicine, 2025, 40(7): 660-665. |
| [7] | LIN Jing, LI Quanle, YU Ting, WANG Huimin, SHEN Min, TU Minmin, CHEN Chuanding, PAN Jingjue, MA Jingxia. Establishment and performance evaluation of candidate reference measurement procedures for serum oxcarbazepine and 10-hydroxy carbamazepine [J]. Laboratory Medicine, 2025, 40(11): 1082-1090. |
| [8] | FAN Xiaoyu, LI Qing, TU Jiaxin, JIN Zhonggan, YU Keying, SUN Hewei, LUO Xialin, JU Yi. Application of inductively coupled plasma mass spectrometry in clinical laboratory medicine [J]. Laboratory Medicine, 2025, 40(11): 1126-1131. |
| [9] | FANG Huiling, JU Yi, OU Yuanzhu, ZHU Yuqing, LI Qing, JIN Zhonggan, ZHAO Xiaojun, FAN Xiaoyu, YU Keying. Current status of liquid chromatography-tandem mass spectrometry in clinical laboratories in Shanghai [J]. Laboratory Medicine, 2024, 39(9): 853-858. |
| [10] | LIN Jing, PAN Qingqing, SHEN Min, XIE Yangmin, JIN Zhonggan, PAN Jingjue, LIU Jiajuan. Establishment and performance evaluation of candidate reference measurement procedures for serum voriconazole [J]. Laboratory Medicine, 2024, 39(7): 661-667. |
| [11] | HUANG Ying, ZHOU Ying, SONG Yunxiao, MAO Junjie, GUAN Chao, ZHAO Jinyan, NI Peiqing. Pulmonary tuberculosis diagnosis model for blood routine test based on machine learning algorithms [J]. Laboratory Medicine, 2024, 39(7): 668-672. |
| [12] | ZHAO Chunhe, SHAO Huihui, CUI Weiqi, XIA Wei, QU Linlin. Progress in application of blood coagulation point-of-care testing [J]. Laboratory Medicine, 2024, 39(7): 709-714. |
| [13] | WU Xinzhe, MAO Haifeng, YANG Jin, ZUO Chunlei, JIN Danting. Clinical application of MALDI-TOF direct droplet culture method in rapid determination of CRKP [J]. Laboratory Medicine, 2024, 39(6): 587-591. |
| [14] | DUAN Xuehan, WU Hua. Application of MALDI-TOF MS technology in clinical microbiological examination [J]. Laboratory Medicine, 2024, 39(4): 410-414. |
| [15] | LI Anqi, ZHANG Shuya, HE Shanna, CHEN Qiaoqiao, LÜ Qi, LÜ Wanfei, LI Chunxian, WANG Weihua, ZHENG Lin. Rapid bacterial identification and drug susceptibility test of blood culture-positive samples [J]. Laboratory Medicine, 2024, 39(3): 243-248. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||